Your browser doesn't support javascript.
loading
Montrer: 20 | 50 | 100
Résultats 1 - 5 de 5
Filtrer
Plus de filtres










Gamme d'année
1.
Growth Horm IGF Res ; 22(3-4): 116-21, 2012.
Article de Anglais | MEDLINE | ID: mdl-22565153

RÉSUMÉ

OBJECTIVE: To compare the effects of two regimens of GH therapy with different target IGF-1 levels on anthropometric parameters, glucose metabolism, lipid profile and cardiac function in adults with GH deficiency (GHD). PATIENTS AND METHODS: Retrospective analysis of 14 GHD adults from Clementino Fraga Filho University Hospital, Rio de Janeiro, Brazil, who were treated with a GH regimen aimed at maintaining serum IGF-1 levels between the median and upper reference limit (high dose group - HDGH) and 18 GHD adults from Federal University Hospital, Curitiba, Brazil, who received a fixed GH dose of 0.2mg/day in the first year of treatment, followed by titration to maintain serum IGF-1 levels between the median and lower reference limit (low dose group - LDGH). All patients were followed for 2 years with analysis of anthropometric parameters, serum levels of IGF-1, glucose, insulin, HOMA-IR, lipid profile, and transthoracic echocardiography. RESULTS: Changes on weight, BMI and waist circumference were similar between the two groups. Insulin levels increased and HOMA-IR worsened in the LDGH group at 1year and improved thereafter. Total cholesterol and triglycerides did not change with therapy. LDL cholesterol reduced in both groups, while HDL-cholesterol significantly increased only in the HDGH group (p=0.007 vs LDGH). No significant variations on echocardiographic parameters were observed. CONCLUSION: The HDGH and LDGH regimens resulted in similar changes on anthropometric, echocardiographic, glucose and lipid parameters in GHD adults, except for increase in HDL cholesterol that was only observed in the HDGH regimen.


Sujet(s)
Glycémie/métabolisme , Hormone de croissance humaine/administration et posologie , Facteur de croissance IGF-I/métabolisme , Adulte , Anthropométrie , Composition corporelle , Brésil , Phénomènes physiologiques cardiovasculaires , Cholestérol/sang , Cholestérol HDL/sang , Cholestérol LDL/sang , Femelle , Hormone de croissance humaine/déficit , Humains , Lipides/sang , Mâle , Adulte d'âge moyen , Études rétrospectives , Triglycéride/sang
2.
Pituitary ; 12(4): 322-9, 2009.
Article de Anglais | MEDLINE | ID: mdl-19390974

RÉSUMÉ

The purpose of this study was to evaluate the effects of 5 years of GH substitution on cardiac structure and function, physical work capacity and blood pressure levels in adults with GH deficiency (GHD). Fourteen patients were clinically assessed every 3 months for 5 years. Transthoracic echocardiography and exercise test were performed at baseline, 24, 48 and 60 months. Blood pressure (BP) was measured by means of ambulatory monitoring of blood pressure at baseline, 6, 12, 24 and 60 months. Left ventricular mass and its index increased progressively during the 5 years of GH substitution (P = 0.008 and 0.007, respectively). There were no significant changes in all others cardiac parameters evaluated. It was observed a significant improve in functional capacity (P < 0.001) and maximal oxygen uptake (P = 0.006) during the treatment. Diurnal systolic BP increased by 15 mmHg (P = 0.024) and diurnal diastolic BP by 4.5 mmHg (P = 0.037). There was no change in dirnal systolic pressure load but a considerable but non-statistically significant reduction in diurnal diastolic pressure load was observed during the study. During the night diastolic BP increased by 4 mmHg (P = 0.012) despite a substantial but non-statistically significant reduction in diastolic pressure load. We observed an increase in the proportion of persons with a non-physiological nocturnal fall (non-dippers) throughout the study (from 36.4% at baseline to 54.6% after 60 months of therapy). We concluded that 5 years of GH replacement promoted positive effects on exercise capacity and maximum oxygen uptake in spite of a modest increase in BP levels and left ventricular mass. Continuous monitoring is mandatory to arrive at further conclusions concerning the effects of GH substitution in adults on cardiovascular parameters with respect to possible unfavorable long term effects.


Sujet(s)
Coeur/effets des médicaments et des substances chimiques , Hormonothérapie substitutive/méthodes , Hormone de croissance humaine/usage thérapeutique , Hypopituitarisme/traitement médicamenteux , Adulte , Pression sanguine/effets des médicaments et des substances chimiques , Échocardiographie , Tolérance à l'effort/effets des médicaments et des substances chimiques , Femelle , Coeur/physiologie , Ventricules cardiaques/effets des médicaments et des substances chimiques , Hormone de croissance humaine/pharmacologie , Humains , Mâle , Adulte d'âge moyen , Études prospectives
3.
Metabolism ; 57(1): 121-9, 2008 Jan.
Article de Anglais | MEDLINE | ID: mdl-18078869

RÉSUMÉ

The benefits of long-term effects of growth hormone (GH) substitution on carbohydrate and lipid metabolism in GH-deficient (GHD) adults are still controversial. The purpose of this study was to evaluate the effects of 5 years of GH substitution on body composition, glucose and lipid metabolism, and carotid artery intima-media thickness (IMT) in GHD adults. Fourteen patients were clinically assessed every 3 months for 5 years. Serum insulin-like growth factor 1 levels, lipid profile, oral glucose tolerance test, and ultrasonography of the carotid arteries were performed at baseline, 6 months, and every year during replacement. Visceral fat was measured by computed tomographic scan at baseline and at 6, 12, 24, and 60 months. The waist circumference was reduced after 6 months but increased during the next months toward baseline values. Visceral fat decreased during the study. Fasting glucose and insulin levels did not change, as well as the homeostasis model assessment of insulin resistance index. Despite an initial increase in frequency of abnormal glucose tolerance, mean 2-hour oral glucose tolerance test glucose levels decreased during the last 2 years. There was an increase in apolipoprotein A-1 levels during the treatment. Apolipoprotein B levels were reduced after 6 months and remained stable thereafter. A reduction in carotid artery IMT was observed during replacement. We concluded that 5 years of GH replacement therapy promoted positive effects on visceral fat, lipid profile, and carotid artery IMT in GHD adults. Long-term therapy improves insulin sensitivity through a reduction in visceral fat, and continuing monitoring is mandatory in terms of glucose metabolism.


Sujet(s)
Hormonothérapie substitutive/méthodes , Hormone de croissance humaine/déficit , Hormone de croissance humaine/usage thérapeutique , Hypopituitarisme/traitement médicamenteux , Adulte , Glycémie/métabolisme , Composition corporelle , Diabète/épidémiologie , Femelle , Études de suivi , Intolérance au glucose/épidémiologie , Hyperglycémie provoquée , Hormone de croissance humaine/effets indésirables , Humains , Hypopituitarisme/sang , Hypopituitarisme/étiologie , Facteur de croissance IGF-I/métabolisme , Mâle , Adulte d'âge moyen
4.
Arq. bras. endocrinol. metab ; 51(9): 1434-1447, dez. 2007. ilus, tab
Article de Portugais | LILACS | ID: lil-471763

RÉSUMÉ

A cetoacidose diabética é uma complicação aguda do Diabetes Mellitus (DM) caracterizada por hiperglicemia, acidose metabólica, desidratação e cetose, na vigência de deficiência profunda de insulina. Acomete principalmente pacientes com DM tipo 1 e geralmente é precipitada por condições infecciosas, uso inadequado de insulina ou desconhecimento do diagnóstico de diabetes. Os autores revisam mecanismos fisiopatológicos, critérios diagnósticos e opções terapêuticas do distúrbio em adultos, bem como suas possíveis complicações.


Diabetic ketoacidosis is an acute complication of Diabetes Mellitus characterized by hyperglycemia, metabolic acidosis, dehydration, and ketosis, in patients with profound insulin deficiency. It occurs predominantly in patients with type 1 diabetes and is frequently precipitated by infections, insulin withdrawal or undiagnosed type 1 diabetes. The authors review its pathophysiology, diagnostic criteria and treatment options in adults, as well as its complications.


Sujet(s)
Adulte , Humains , Acidocétose diabétique/physiopathologie , Diabète de type 1/complications , Diabète de type 1/diagnostic , Diabète de type 1/physiopathologie , /complications , /diagnostic , /physiopathologie , Acidocétose diabétique/diagnostic , Acidocétose diabétique/thérapie
5.
Arq Bras Endocrinol Metabol ; 51(9): 1434-47, 2007 Dec.
Article de Portugais | MEDLINE | ID: mdl-18209885

RÉSUMÉ

Diabetic ketoacidosis is an acute complication of Diabetes Mellitus characterized by hyperglycemia, metabolic acidosis, dehydration, and ketosis, in patients with profound insulin deficiency. It occurs predominantly in patients with type 1 diabetes and is frequently precipitated by infections, insulin withdrawal or undiagnosed type 1 diabetes. The authors review its pathophysiology, diagnostic criteria and treatment options in adults, as well as its complications.


Sujet(s)
Acidocétose diabétique/physiopathologie , Adulte , Diabète de type 1/complications , Diabète de type 1/diagnostic , Diabète de type 1/physiopathologie , Diabète de type 2/complications , Diabète de type 2/diagnostic , Diabète de type 2/physiopathologie , Acidocétose diabétique/diagnostic , Acidocétose diabétique/thérapie , Humains
SÉLECTION CITATIONS
DÉTAIL DE RECHERCHE
...